Download PDF

1. Company Snapshot

1.a. Company Description

NeuroOne Medical Technologies Corporation operates as a medical technology company.The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders.It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode.


The company is based in Eden Prairie, Minnesota.

Show Full description

1.b. Last Insights on NMTC

NeuroOne Medical Technologies Corporation faced challenges due to increasing competition in the medical technology sector. Despite receiving FDA clearance for its OneRF Trigeminal Nerve Ablation System to treat facial pain, the company's growth prospects are uncertain. A recent special call highlighted concerns about the company's financials, with investors scrutinizing its revenue streams. With no recent earnings release to alleviate concerns, NeuroOne's focus on innovative solutions, such as its minimally invasive OneRF system, may not be enough to offset market skepticism. (Source: Bloomberg)

1.c. Company Highlights

2. NeuroOne Medical Technologies Corporation: Seizure Freedom Milestones and Expanding Market Opportunities

NeuroOne Medical Technologies Corporation reported a significant increase in product revenue, which rose 105% to $1.7 million, with product gross margins expanding to 53.9% from 34.1% in the same quarter of fiscal year 2024. The company's EPS came in at -$0.03, beating estimates of -$0.05. The financial performance was driven by the company's focus on product development and market expansion. As the company continues to execute on its growth strategy, its financial guidance for fiscal year 2025 remains unchanged, with expected product revenue in the range of $8 million to $10 million, representing an increase of 132% to 190% over fiscal year 2024.

Publication Date: Aug -19

📋 Highlights
  • Product Revenue Surge: Product revenue rose 105% to $1.7 million, with gross margins improving to 53.9% (up from 34.1% YoY).
  • Landmark Patient Outcome: First patient achieved one-year seizure freedom following treatment with the OneRF ablation system.
  • Expanding Market Opportunities: Pursuing FDA 510(k) clearance for facial pain and lower back pain ablation, targeting late 2025 revenue potential.
  • Upgraded Financial Guidance: FY2025 product revenue guidance raised to $8–10 million (132–190% YoY growth), with gross margins of 50–53%.
  • Strong Liquidity Position: $8 million cash/cash equivalents and $8.7 million working capital (June 2025), funded through FY2026 with $8.2 million recent financing.

Financial Performance and Guidance

The company's financial guidance for fiscal year 2025 remains unchanged, with expected product revenue in the range of $8 million to $10 million, representing an increase of 132% to 190% over fiscal year 2024. Product gross margin expectations have been increased to 50% to 53%. The company had cash and cash equivalents of $8 million as of June 30, 2025, and working capital of $8.7 million, with no debt outstanding. According to the company's management, "we believe we are funded through at least fiscal year 2026, potentially longer if key milestones are achieved," following an oversubscribed financing round in April that raised $8.2 million in net proceeds.

Market Opportunities and Product Development

The company is pursuing additional market opportunities, including pain management, with a 510(k) submission to the FDA for clearance to market an ablation technology to treat facial pain, or trigeminal neuralgia. If cleared, potential revenues could be generated late in calendar year 2025. Another application being pursued is the treatment of lower back pain through basivertebral nerve ablation. The company's focus on expanding its product portfolio and market reach is expected to drive growth in the coming years. Analysts estimate next year's revenue growth at 41.8%, reflecting the company's potential for long-term growth.

Valuation Metrics

At current prices, NeuroOne Medical Technologies Corporation trades at a P/S ratio of 6.99, which may suggest that the stock is trading at a premium to its peers. The company's EV/EBITDA ratio is -6.86, which may indicate that the stock is undervalued based on its earnings before interest, taxes, depreciation, and amortization. Additionally, the company's free cash flow yield is -12.31%, which may suggest that the stock is not generating sufficient cash flows. However, it's worth noting that the company has a high ROIC of -235.17% and ROE of -334.57%, which may indicate that the company is investing heavily in its growth strategy.

3. NewsRoom

Card image cap

NeuroOne Medical Technologies Corporation - Special Call

Oct -07

Source: seekingalpha.com

Card image cap

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

Sep -08

Source: globenewswire.com

Card image cap

NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment

Aug -19

Source: zacks.com

Card image cap

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Aug -18

Source: globenewswire.com

Card image cap

NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript

Aug -14

Source: seekingalpha.com

Card image cap

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

Aug -14

Source: globenewswire.com

Card image cap

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update

Jul -31

Source: globenewswire.com

Card image cap

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office

Jul -23

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.49%)

6. Segments

Strip/Grid Products, Stereoelectrocencephalography Products and Electrode Cable Assembly Products

Expected Growth: 9.0%

NeuroOne Medical Technologies Corporation's Strip/Grid Products, Stereoelectrocencephalography Products, and Electrode Cable Assembly Products are driven by increasing demand for minimally invasive neurosurgical procedures, advancements in EEG technology, and growing adoption of precision medicine. The 9.0% growth rate is also fueled by expanding applications in neurology, psychiatry, and sleep disorder diagnosis, as well as increasing investments in research and development.

Collaborations

Expected Growth: 10.47%

NeuroOne Medical Technologies Corporation's 10.47% growth is driven by strategic collaborations, expanding product portfolio, and increasing adoption of minimally invasive neurosurgical technologies. Partnerships with leading medical institutions and research organizations have accelerated innovation, while growing demand for neurodiagnostic and neuromodulation solutions has fueled revenue growth.

7. Detailed Products

Cortex

A thin-film electrode array designed for chronic recording and stimulation of the brain, providing high-resolution neural signals for research and clinical applications.

Syringe Electrode

A minimally invasive, injectable electrode for recording and stimulating neural activity, suitable for a wide range of applications, including neurology, psychiatry, and neurosurgery.

NeuroLite

A thin, flexible, and lightweight electrode array designed for acute and chronic neural recording and stimulation, suitable for a variety of applications, including brain-computer interfaces and neuroprosthetics.

8. NeuroOne Medical Technologies Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

NeuroOne Medical Technologies Corporation operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new technologies.

Bargaining Power Of Customers

NeuroOne Medical Technologies Corporation's customers are primarily hospitals and medical institutions, which have limited bargaining power due to the specialized nature of the company's products.

Bargaining Power Of Suppliers

NeuroOne Medical Technologies Corporation relies on a few key suppliers for its raw materials, which gives them some bargaining power, but the company's strong relationships with its suppliers mitigate this risk.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with NeuroOne Medical Technologies Corporation.

Intensity Of Rivalry

The medical technology industry is highly competitive, with several established players competing for market share, which increases the intensity of rivalry for NeuroOne Medical Technologies Corporation.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.87%
Debt Cost 3.95%
Equity Weight 97.13%
Equity Cost 9.24%
WACC 9.08%
Leverage 2.95%

11. Quality Control: NeuroOne Medical Technologies Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BioSig Technologies

A-Score: 4.9/10

Value: 8.0

Growth: 6.9

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Nevro

A-Score: 4.7/10

Value: 9.2

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 7.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
ClearPoint Neuro

A-Score: 4.2/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NeuroOne Medical Technologies

A-Score: 3.7/10

Value: 6.8

Growth: 6.1

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Accelerate Diagnostics

A-Score: 3.5/10

Value: 10.0

Growth: 5.6

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Cytek Biosciences

A-Score: 3.4/10

Value: 6.3

Growth: 7.0

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.61$

Current Price

0.61$

Potential

-0.00%

Expected Cash-Flows